Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma

29 Jun 2021

Abstract excerpt

Objectives This study aims to investigate the underlying mechanisms of KAT2A/MCT1 axis in renal cell carcinoma (RCC), providing potential therapeutic targets. Methods We obtained the expression data of KAT2A and MCT1 from The Cancer Genome Atlas Kidney Clear Cell Carcinoma (TCGA-KIRC) and International Cancer Genome Consortium (ICGC) databases. Differential analysis was conducted via the limma package. The CCK8...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Microtubule and mitosis dynamics
Share to Renal and related cancers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34268311
DOI: 10.3389/fcell.2021.690796

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell CarcinomaPMID 34268311Read ↗

The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinomaSemantic proximity Read ↗

Lysine methyltransferase 5C increases the proliferation and metastatic abilities of clear cell renal cell carcinoma via aerobic glycolysisSemantic proximity Read ↗

The molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy.Semantic proximity Read ↗

TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF SignalingSemantic proximity Read ↗

KMT2B promotes the growth of renal cell carcinoma via upregulation of SNHG12 expression and promotion of CEP55 transcriptionSemantic proximity Read ↗

The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell CarcinomaSemantic proximity Read ↗

Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.Semantic proximity Read ↗

Overexpression of PKMYT1 Facilitates Tumor Development and Is Correlated with Poor Prognosis in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

PKMYT1, exacerbating the progression of clear cell renal cell carcinoma, is implied as a biomarker for the diagnosis and prognosisSemantic proximity Read ↗

Anti-Tumor Role of CAMK2B in Remodeling the Stromal Microenvironment and Inhibiting Proliferation in Papillary Renal Cell CarcinomaSemantic proximity Read ↗

Molecular and immunologic markers of kidney cancer—potential applications in predictive, preventive and personalized medicineSemantic proximity Read ↗

Identification of a novel papillary renal cell carcinoma molecular subtype characterized by HIF-pathway over-activationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.